Gilead Sciences shares drop more than 3% after positive HIV sales outlook fails to lift sentiment

Traders Union
All News
Stocks
Gilead Sciences drops 3.35% today

Highlights

Gilead Sciences reported second-quarter 2026 revenue of $7.8 billion, up 10.2% year over year and above consensus estimates.
HIV franchise strength drove results as PrEP sales exceeded $1 billion and patient persistency for Yeztugo surpassed 70% at six months.
Gilead Sciences stock faces elevated volatility with sideways trading expected in the $127.08 to $135.22 range, though underlying indicators remain mixed.

Revenue growth and HIV sales surge offset by ongoing market skepticism

Gilead Sciences reported second-quarter 2026 revenue of $7.8 billion, an increase of 10.2% year over year that exceeded analyst estimates. The company’s HIV prevention portfolio was a key driver, with quarterly PrEP sales surpassing $1 billion for the first time and Yeztugo reporting over 70% patient persistency at six months. Gilead raised its full-year HIV revenue growth outlook and increased the midpoint of its base business sales guidance, alongside a declared quarterly dividend and plans for a $5 billion acquisition of Tubulis, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Gilead's strong earnings and bullish guidance overshadowed by technical weakness. He notes that the stock remains capped below all major resistance levels and that mixed momentum signals reflect persistent uncertainty. The news of surging PrEP sales and a major acquisition have failed to reverse recent selling pressure. Bearish sentiment dominates intraday action, with the price stuck near session lows and volatility spiking above 6%. "Despite a fundamentally positive backdrop, risk remains elevated as technical signals point to ongoing downward pressure and limited upside for the time being."

Viktoras Karapetjanc, expert at Traders Union, highlights Gilead's robust year-over-year growth and impressive PrEP momentum as catalysts for future performance. He believes the raised HIV revenue guidance and strategic M&A demonstrate management's confidence. While short-term volatility persists, the broader market positioning remains supportive for a bullish turn. "With fundamentals strengthening and new revenue drivers emerging, I see further upside ahead as bullish demand reasserts itself."

Jainam Mehta, market strategist, observes that Gilead is trapped between major moving averages, signaling indecision. He notes the divergence in short-term indicators, suggesting potential for tactical range trading. The elevated volatility may attract swing traders if clear direction emerges. "A break above $131.92 could trigger a tactical long, while a slide below $129.84 may offer a quick short opportunity."

Conflicting momentum and resistance cap gains as intraday volatility rises

Gilead Sciences is trading below its 20-day moving average at $132.18 and its 200-day moving average at $131.92, but remains above the medium-term 50-day average at $129.84. This configuration signals short- and long-term pressure from sellers, with resistance also reinforced by the Ichimoku Kijun at $132.35. Immediate support is found near the 50-day average at $129.84, and near-term resistance is set at the 200-day level. Momentum readings present a mixed picture: the Moving Average Convergence Divergence (MACD) and Relative Strength Index (RSI) both indicate underlying buying interest, but the Average Directional Index (ADX) suggests a weak trend and the Stochastic RSI, Commodity Channel Index (CCI), and Awesome Oscillator are all neutral. Bull/Bear Power (BBP) remains positive at 3.4, confirming that buyers dominate intraday momentum, though it signals an overbought condition. The stock is trading at $130.72, down $4.53 or 3.35% intraday after opening with an upside gap of 0.55%. Price is currently near the day’s low, and volatility amplitude today is elevated at 6.12%, indicating sustained pressure after the initial gap. Several momentum and oscillator signals conflict, which highlights growing uncertainty in the intraday tone.

Earlier, analysts noted that Gilead Sciences was experiencing ongoing downside pressure and a period of sideways consolidation as technical signals limited the probability of immediate upside. The current analysis builds on this view by highlighting mixed momentum in the face of strong fundamentals, with traders advised to monitor price reactions at the $129.84 support and $131.92 resistance levels for the next decisive move.

Source of Data: GILD Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.